DE69132519D1 - Quinolin-Derivate - Google Patents

Quinolin-Derivate

Info

Publication number
DE69132519D1
DE69132519D1 DE69132519T DE69132519T DE69132519D1 DE 69132519 D1 DE69132519 D1 DE 69132519D1 DE 69132519 T DE69132519 T DE 69132519T DE 69132519 T DE69132519 T DE 69132519T DE 69132519 D1 DE69132519 D1 DE 69132519D1
Authority
DE
Germany
Prior art keywords
quinoline derivatives
quinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132519T
Other languages
English (en)
Other versions
DE69132519T2 (de
Inventor
Hiroshi Hasegawa
Kazuo Isomae
Takeshi Kotsugai
Noriaki Shioiri
Kumiko Sekine
Naokata Taido
Susumu Sato
Tadayuki Kuraishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Publication of DE69132519D1 publication Critical patent/DE69132519D1/de
Application granted granted Critical
Publication of DE69132519T2 publication Critical patent/DE69132519T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69132519T 1990-10-19 1991-10-15 Chinolinderivate Expired - Fee Related DE69132519T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28109490 1990-10-19
JP28109390 1990-10-19

Publications (2)

Publication Number Publication Date
DE69132519D1 true DE69132519D1 (de) 2001-03-01
DE69132519T2 DE69132519T2 (de) 2001-06-13

Family

ID=26554052

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132519T Expired - Fee Related DE69132519T2 (de) 1990-10-19 1991-10-15 Chinolinderivate

Country Status (8)

Country Link
US (2) US5190951A (de)
EP (2) EP0481429B1 (de)
KR (1) KR100206200B1 (de)
CA (1) CA2053640C (de)
DE (1) DE69132519T2 (de)
ES (1) ES2156853T3 (de)
HK (1) HK1011351A1 (de)
SG (1) SG44523A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
ES2167569T3 (es) * 1995-06-15 2002-05-16 Upjohn Co Uso de imidazo(1,5-a)quinolonas como agentes neuroprotectores.
JP2004508272A (ja) * 1998-06-10 2004-03-18 アリーナ・フアーマシユーチカルズ・インコーポレーテツド アセチルコリンエンハンサー
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
CN1163224C (zh) 1998-09-30 2004-08-25 武田药品工业株式会社 改善膀胱***能力的药物
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
JP4916662B2 (ja) 2002-06-19 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ホスホジエステラーゼ阻害剤として有用な置換2,4−ジヒドロ−ピロロ(3,4−b)−キノリン−9−オン誘導体
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
US7425556B2 (en) * 2005-12-20 2008-09-16 Astrazeneca Ab Compounds and uses thereof
AR067027A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a.
AR067028A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Compuestos y usos de los mismos 849
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
EP3034079B1 (de) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazinderivate, zusammensetzungen und verfahren zur behandlung von kognitiven störungen
WO2012154879A2 (en) * 2011-05-09 2012-11-15 Van Andel Research Institute Autophagy inhibitors
CN102875602B (zh) * 2012-10-25 2015-05-20 江苏神龙药业有限公司 一种米诺膦酸水合物的制备方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (de) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam zur verbesserung der kognitiven funktion
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
IL256354B (en) 2015-06-19 2022-09-01 Agenebio Inc History of benzodiazepines, preparations and their use for the treatment of cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
WO2019246300A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112608326B (zh) * 2021-01-22 2021-10-01 河南大学 呋喃并[2,3-b]喹啉-3,4(2H,9H)-二酮衍生物、其制备方法及应用
CN114989180B (zh) * 2022-05-26 2024-06-04 广东海洋大学 杨叶肖槿内生真菌来源的化合物及其制备方法与应用
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2507076B2 (ja) * 1989-08-11 1996-06-12 株式会社クボタ カ―ド式自動販売機
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5240934A (en) * 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives

Also Published As

Publication number Publication date
ES2156853T3 (es) 2001-08-01
EP0481429A2 (de) 1992-04-22
EP0481429A3 (en) 1992-08-19
DE69132519T2 (de) 2001-06-13
KR100206200B1 (ko) 1999-07-01
US5300517A (en) 1994-04-05
SG44523A1 (en) 1997-12-19
KR920008024A (ko) 1992-05-27
HK1011351A1 (en) 1999-07-09
EP0987262A1 (de) 2000-03-22
EP0481429B1 (de) 2001-01-24
CA2053640C (en) 2001-12-25
US5190951A (en) 1993-03-02
CA2053640A1 (en) 1992-04-20

Similar Documents

Publication Publication Date Title
DE69132519D1 (de) Quinolin-Derivate
DE69119329D1 (de) Actinonin-Derivate
NO932176L (no) Kinolin-, naftyridin- og pyridobenzoksazinderivater
DK0382185T3 (da) Carbostyrilderivater
FI925523A0 (fi) Hydroxi- och alkoxipyridinderivat
DE68925405D1 (de) Carbostyril-Derivate
MX9201823A (es) Derivados de quinolina.
FI923931A (fi) Anordning foer granskning av insidan av en foergrenad roerlinje
DE69125099D1 (de) Indolderivate
MX9100018A (es) Histidinas sustituidas
ATE144765T1 (de) Hiv-hemmende benzenacetamidderivate
DK391189D0 (da) Carbostyrilderivater
DE69130255D1 (de) Oxadolderivate
DK0472733T3 (da) Phenantrenderivater
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
FI925805A (fi) Framstaellning av kompositmaterial
NO930520D0 (no) Bifenyl-substituerte kinolinderivater
FI925609A (fi) Foerfarande foer framstaellning av sykliska sulfater
BR9107169A (pt) Derivados de isoquinolina fungicidas
DK82189A (da) Substituerede quinolinderivater
DK81989A (da) Substituerede quinolinderivater
DE69113284D1 (de) Chinolinderivat.
BR9205939A (pt) Derivados de 4-aril-3-(heteroalilureído)quinolina
FI925544A0 (fi) Bensoesyraderivat foer behandling av leukotrienassocierade sjukdomar
BR9104543A (pt) Derivados de triazolpiridazina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOMEDIX CO., LTD, TOKIO/TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: HISAMITSU MEDICAL CO., LTD., TOKIO/TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: HISAMITSU PHARMACEUTICAL CO., INC., TOSU, SAGA, JP

8339 Ceased/non-payment of the annual fee